Why the study?
Does verapamil reduce the risk of non-fatal reinfarction or death in patients recovering from acute myocardial infarction?
Does verapamil reduce the risk of non-fatal reinfarction or death in patients recovering from acute myocardial infarction?
Answers are grounded in this paper and cite their sources.
Verapamil showed a non-significant trend towards reducing major events in post-MI patients with exercise-induced ST-segment depression, suggesting potential benefit in those with residual ischemia.
The present study tested the hypothesis that the increased risk in patients with exercise-provoked ST-segment depression recovering from acute myocardial infarction could by abolished by anti-ischaemic medical intervention. Prior to discharge a symptom-limited exercise test was carried out. Patients were then double-blindly randomized to treatment with either verapamil 120 mg t.i.d. or placebo, and observed for up to 18 months (mean 17 months). End-point was first major event; i.e. non-fatal reinfarction or death. Two-hundred-and-ninety-eight patients were included. Forty-four patients with and 111 without exercise-induced ischaemia were randomized to verapamil and 39 and 104 respectively, to placebo. The overall number of events was 12.5%. In patients without ST-segment depression, 12.5% in the placebo group (hazard = 1) and 12.6% in the verapamil group (hazard = 1.13) had an event (NS). In patients with ST-segment depression 15.4% in the placebo group (hazard = 1.20) and 9.1% in the verapamil group (hazard = 0.85) had an event (NS). The latter reduction (41%) supports the hypothesis that patients with ST-segment depression, i.e. residual myocardial ischaemia, are those who benefit from anti-ischaemic intervention after myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Jespersen et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: